Enliven Therapeutics(ELVN) - 2024 Q4 - Annual Results

Exhibit 99.1 Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update Updated Phase 1 data for ELVN-001 expected mid-2025 as positive enrollment momentum continues Expected monotherapy and combination data from the ELVN-002 Phase 1 trials in second half of 2025 • In 2024, the Company announced positive initial data from the ongoing Phase 1 clinical trial that compared favorably to the precedent Phase 1 trials for the approved BCR::ABL1 tyrosine kinase i ...